HKHiroaki Kanai

Hiroaki Kanai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiroaki Kanai has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Kobayashi

    Department of Pediatrics, Faculty of Medicine University of Yamanashi Chuo Yamanashi Japan

    5 shared publications
  • Emi Sawanobori

    Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

    4 shared publications
  • Kanji Sugita

    Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

    4 shared publications
  • Kosuke Higashida

    Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

    4 shared publications
  • Kyoko Matsushita

    Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo-city, Yamanashi, 409-3898, Japan

    3 shared publications
  • Emi Sawanobori

    Department of Pediatrics, Faculty of Medicine University of Yamanashi Chuo Yamanashi Japan

    2 shared publications

Latest Publications

  • Open Access

    Serum Growth Differentiation Factor 15 Levels in School‐Aged Children Born Preterm

    by Miwa Goto, Anna Kobayashi, Hiroaki Kanai, Nobuyuki Katsumata, Atsushi Naito, Emi Sawanobori

  • Differentiating Society for Fetal Urology Grades 2 and 3 Hydronephrosis: Diagnostic Accuracy of Resident Physicians

    by Hiroaki Kanai, Miwa Goto, Anna Kobayashi, Emi Sawanobori

    Background: The Society for Fetal Urology (SFU) grading system is widely used to assess the severity of congenital hydronephrosis (CHN). Distinguishing between Grades 2 and 3 is clinically critical yet diagnostically challenging because of vague definitions. Grades ≤ 2 are usually observed, and Grades ≥ 3 require closer follow‐up; therefore, the 2–3 boundary represents a critical threshold. However, the diagnostic accuracy of inexperienced physicians remains unassessed. Methods: Six kidneys (three per grade) with consensus diagnoses by four pediatric nephrology experts were selected as representative cases. Three sagittal static ultrasound images were selected for each kidney. The images were anonymized except for age, sex, and laterality. Twenty‐four evaluators (12 first‐ or second‐year junior residents and 12 non‐pediatric senior residents with 3–5 years of experience), all without CHN experience, independently graded each case after self‐study using published definitions and sample images. Results: Agreement with the expert consensus was 40% (Fleiss' κ = 0.05). The agreement was 47% for Grade 2 (κ = 0.09) and 33% for Grade 3 (κ = −0.03). Undergrading of Grade 3 as ≤ 2 occurred in 56% of responses, exceeding the overgrading of Grade 2 as ≥ 3 (22%). Agreement varied by case, ranging from 54% (Grade 2 kidney “a”) to 25% (Grade 3 kidney “f”). No significant differences were observed between the junior and senior residents. Conclusions: Inexperienced physicians demonstrated extremely poor reproducibility in distinguishing SFU Grades 2 and 3, with a strong and consistent tendency toward underestimation. Frequent misclassification and marked case‐to‐case variability underscore the urgent need for improved educational strategies and diagnostic aids.

  • Urolithiasis with overdiagnosed nutcracker syndrome in a pediatric patient

    by Hiroaki Kanai, Hiroki Sato, Yoshichika Takei


  • Urinary fibrin/fibrinogen degradation products measured using an anti‐fibrinogen antibody predict orthostatic proteinuria

    by Hiroaki Kanai, Emi Sawanobori, Anna Kobayashi, Miwa Goto, Kosuke Higashida, Kanji Sugita

    Background: The aim of this study was to assess the diagnostic value of urinary fibrin/fibrinogen degradation products (uFDP) measured using an anti‐fibrinogen antibody in patients with orthostatic proteinuria (OP), and their use in differentiating between OP and glomerulonephritis (GN).Methods: uFDP were measured using first urine in the morning (supine) and non‐first urine during a hospital visit (upright) and then normalized to urine creatinine (uFDP/Cr, ng/mgCr). We compared (i) OP patients (n = 16); (ii) those in remission from nephrotic syndrome (NS, n = 14) and from GN (IgA nephropathy [IgAN], n = 14; Henoch–Schönlein purpura nephritis [HSPN], n = 12); and (iii) those with active GN (IgAN, n = 12; HSPN, n = 19).Results: The uFDP/Cr ratio increased from supine to upright urine in patients with OP (P < 0.001), but decreased in one case. uFDP were excreted in supine urine in 94% of OP patients, with no excretion in NS remission patients or in 92% of GN remission patients (P < 0.001 for both). uFDP/Cr in supine urine was similar between the OP and active GN patients (P = 0.40), whereas proteinuria in supine urine was in the normal range in all OP patients, but was significantly higher in upright urine in the OP patients (P < 0.001). In upright urine, urinary protein/creatinine ratio was significantly lower in patients with OP than in those with active GN (P = 0.005). A uFDP/Cr ratio cut‐off of 1,108 ng/mgCr in upright urine correctly differentiated OP from active GN, with a sensitivity of 87.5% and a specificity of 100%.Conclusion: Comparison of uFDP levels in supine/upright urine can be reliable for diagnosing OP and for differentiating it from active GN.


  • Open Access

    Community-acquired methicillin-resistant Staphylococcus epidermidis pyelonephritis in a child: a case report

    by Hiroaki Kanai, Hiroki Sato, Yoshichika Takei

    Staphylococcus epidermidis is currently the most frequent pathogen of opportunistic and nosocomial infections worldwide. Most cases of Staphylococcus epidermidis infections are associated with indwelling medical devices and/or immunocompromised conditions. Community-acquired urinary tract infections are rare, particularly among pediatric populations, and clinicians often do not consider Staphylococcus epidermidis as a uropathogen.


  • Open Access

    Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient

    by Hiroaki Kanai, Anna Kobayashi, Kyoko Matsushita, Emi Sawanobori, Kanji Sugita, Kosuke Higashida

    Henoch-Schönlein purpura (HSP) is a common self-limited vasculitis in children. The long-term prognosis depends on renal involvement. In severe Henoch-Schönlein purpura nephritis (HSPN) patients, >50 % have crescent formation and nephrotic syndrome that are important predicted outcomes. Therefore, for such patients, an aggressive immunosuppressive therapy is needed to prevent the progression. However, there is no consensus for an appropriate therapeutic regimen for severe pediatric HSPN patients. In this paper, we have reported on a 6-year-old boy who presented with HSPN with nephrotic syndrome and severe histopathological abnormalities; he was diagnosed with International Study of Kidney Disease in Children (ISKDC) grade IVb. Despite treatment with methylprednisolone pulse therapy, followed by oral prednisolone and dipyridamole; the nephrotic syndrome persisted. Subsequently, intravenous cyclophosphamide therapy (IVCY) (500–1,000 mg m−2 once a month for 7 months; total 6,000 mg m−2) was administered, followed by azathioprine and enarapril. Within 7 months of disease onset, complete remission was achieved. After 22 months of the initial renal biopsy, the second biopsy was performed to confirm treatment efficacy. Histopathological findings improved, and ISKDC grade IIIa was diagnosed. Even after 5 years of HSPN onset, complete remission and normal renal function is maintained. Although our evidence is restricted to single patient, we have shown that MPT and IVCY combined with cocktail therapy may be an effective treatment for severe pediatric HSPN.


  • Open Access

    A Puzzling Cause of Relapsing Proteinuria:When Treatment Causes the Disease

    by Hiroaki Kanai, Emi Sawanobori, Anna Kobayashi, Kyoko Matsushita, Kanji Sugita, Kosuke Higashida


  • Open Access

    Hyponatremia in patients with respiratory syncytial virus bronchiolitis

    by Hiroaki Kanai, Sato, Ichihashi, Yuko Sato

    Children with pulmonary diseases are at risk of developing hyponatremia (serum sodium concentrations <136 mEq/L). The aim of this study was to define the clinical and laboratory characteristics of respiratory syncytial virus (RSV) bronchiolitis in patients with hyponatremia and determine the associated risk factors. Medical data of 105 children (56 boys, 49 girls; mean age ± standard deviation: 9.1 ± 8.9 months) with RSV bronchiolitis were retrospectively analyzed. At admission, 35.2% of all patients, 13% of the <12-month-old patients, and 58.8% of the 12–35-month-old patients had hyponatremia. The results show that the development of hyponatremia in inpatients with RSV bronchiolitis is associated with age (12–35 months), body temperature, high fever (≥38.5°C), duration of fever until hospitalization, and high C-reactive protein level at admission. These results indicate that hyponatremia occurs in patients with RSV bronchiolitis exhibiting severe inflammation assessed by fever severity and C-reactive protein level. The use of isotonic fluids is recommended for parenteral therapy of patients with RSV bronchiolitis with risk of developing hyponatremia.


  • Open Access

    Early Treatment with Methylprednisolone Pulse Therapy Combined with Tonsillectomy for Heavy Proteinuric Henoch-Schönlein Purpura Nephritis in Children

    by Hiroaki Kanai, Emi Sawanobori, Anna Kobayashi, Kyoko Matsushita, Kanji Sugita, Kosuke Higashida

    Background: There is no clear consensus as to which patients with Henoch-Schönlein purpura nephritis (HSPN) at risk of a poor outcome should be treated and what therapeutic regimen should be used. Methods: Nine children with heavy proteinuric HSPN received prompt initiation of methylprednisolone pulse therapy (MPT) combined with tonsillectomy in a prospective study. Results: At presentation, the mean values for the patients’ urine protein excretion (early-morning urinary protein/creatinine ratio), serum IgA, activity index (AI), and chronicity index (CI) were 5.0 ± 5.6 g/g Cr, 135.6 ± 56.5 mg/dl, 4.0 ± 0.7, and 1.7 ± 1.3, respectively. At the second biopsy, conducted approximately 24 months after initiation of therapy, the patients’ serum albumin had significantly increased (4.4 ± 0.2, p < 0.01), and the serum IgA and AI had significantly decreased (88.1 ± 30.8 mg/dl, p < 0.05; 2.0 ± 1.2, p < 0.01, respectively), whereas the CI remained unchanged. Proteinuria disappeared within 24 months in all but 1 patient, and hematuria disappeared within 38 months in all patients. No patient showed renal impairment or experienced a recurrence and/or exacerbation of HSP/HSPN. Conclusions: Early treatment with MPT combined with tonsillectomy is effective in ameliorating the histopathological progression and improving the clinical course of children with heavy proteinuric HSPN.